ADMA Biologics ADMA Operating And Financing Lease Liability
Operating And Financing Lease Liability at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept adma:OperatingAndFinancingLeaseLiability.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's operating and financing lease liability.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's operating and financing lease liability?
- ADMA Biologics (ADMA) reported operating and financing lease liability of $7.5M in Q1 2026.
- How has ADMA Biologics's operating and financing lease liability changed year-over-year?
- ADMA Biologics's operating and financing lease liability decreased by 2.6% year-over-year, from $7.7M to $7.5M.
- What is the long-term trend for ADMA Biologics's operating and financing lease liability?
- Over 4 years (2021 to 2025), ADMA Biologics's operating and financing lease liability has grown at a -1.3% compound annual growth rate (CAGR), from $8.1M to $7.7M.
- What does operating and financing lease liability mean?
- This metric represents the total present value of future lease payments for both operating and financing leases recognized on the balance sheet. It reflects the company's long-term contractual obligations to pay for the use of assets such as plasma collection centers, manufacturing facilities, or equipment. Monitoring this figure is essential for assessing the company's total debt-like obligations and overall financial leverage.